BHVN
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Biohaven’s clinical data for BHV-1530, a novel FGFR3-directed ADC with a proprietary TopoI payload, selected for an oral presentation at the 2026 EORTC-NCI-AACR SymposiumSep 28, 2026
- Jury awards Biohaven and Yale $4 million in trade secret case against Avilar Therapeutics and RA CapitalJul 27, 2026
- Biohaven will present new clinical data on BHV-1530, an FGFR3-targeted ADC, at the ESMO CongressJul 21, 2026
- Biohaven completed enrollment in the pivotal RISE 3 focal epilepsy study of opakalimJul 1, 2026
- Biohaven initiated a pivotal Phase 3 trial of BHV-1300 for Graves' diseaseJun 29, 2026